CL2023003396A1 - Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos. - Google Patents
Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos.Info
- Publication number
- CL2023003396A1 CL2023003396A1 CL2023003396A CL2023003396A CL2023003396A1 CL 2023003396 A1 CL2023003396 A1 CL 2023003396A1 CL 2023003396 A CL2023003396 A CL 2023003396A CL 2023003396 A CL2023003396 A CL 2023003396A CL 2023003396 A1 CL2023003396 A1 CL 2023003396A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- extended
- vegf antagonist
- ocular disorders
- angiogenic ocular
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000022873 Ocular disease Diseases 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 230000002491 angiogenic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189541P | 2021-05-17 | 2021-05-17 | |
| US202163235398P | 2021-08-20 | 2021-08-20 | |
| US202263297420P | 2022-01-07 | 2022-01-07 | |
| US202263306315P | 2022-02-03 | 2022-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003396A1 true CL2023003396A1 (es) | 2024-06-07 |
Family
ID=81975181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003396A CL2023003396A1 (es) | 2021-05-17 | 2023-11-14 | Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos. |
| CL2024002972A CL2024002972A1 (es) | 2021-05-17 | 2024-10-02 | Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos. |
| CL2025001269A CL2025001269A1 (es) | 2021-05-17 | 2025-04-29 | Antagonistas del vegf en dosis alta para el tratamiento de trastornos oculares angiogénicos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002972A CL2024002972A1 (es) | 2021-05-17 | 2024-10-02 | Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos. |
| CL2025001269A CL2025001269A1 (es) | 2021-05-17 | 2025-04-29 | Antagonistas del vegf en dosis alta para el tratamiento de trastornos oculares angiogénicos. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230302085A1 (enExample) |
| EP (2) | EP4647125A3 (enExample) |
| JP (1) | JP2024519629A (enExample) |
| KR (1) | KR20240008821A (enExample) |
| AU (2) | AU2022275786C1 (enExample) |
| BR (1) | BR112023023002A2 (enExample) |
| CA (1) | CA3190663A1 (enExample) |
| CL (3) | CL2023003396A1 (enExample) |
| DK (1) | DK4185318T3 (enExample) |
| ES (1) | ES3041647T3 (enExample) |
| FI (1) | FI4185318T3 (enExample) |
| HR (1) | HRP20251282T8 (enExample) |
| IL (1) | IL308505A (enExample) |
| JO (1) | JOP20230283A1 (enExample) |
| LT (1) | LT4185318T (enExample) |
| MX (1) | MX2023013554A (enExample) |
| PE (1) | PE20240922A1 (enExample) |
| PL (1) | PL4185318T3 (enExample) |
| PT (1) | PT4185318T (enExample) |
| RS (1) | RS67369B1 (enExample) |
| SI (1) | SI4185318T1 (enExample) |
| TW (1) | TW202313095A (enExample) |
| WO (1) | WO2022245739A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| TW202400214A (zh) * | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
| US20230295266A1 (en) * | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) * | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
| KR20260096819A (ko) * | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| CA2866232A1 (en) | 2012-05-25 | 2013-11-28 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015173260A1 (en) | 2014-05-12 | 2015-11-19 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| IL318292A (en) | 2017-12-13 | 2025-03-01 | Regeneron Pharma | Devices and methods for administering precise doses |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| AU2020345174A1 (en) * | 2019-09-12 | 2022-03-31 | Lupin Limited | Modified dosing of VEGF inhibitors for ophthalmic use |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021129658A1 (zh) | 2019-12-24 | 2021-07-01 | 信达生物制药(苏州)有限公司 | 融合蛋白在治疗年龄相关性黄斑变性中的应用 |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US20230295266A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| TW202400214A (zh) | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
-
2022
- 2022-05-16 FI FIEP22728724.0T patent/FI4185318T3/fi active
- 2022-05-16 IL IL308505A patent/IL308505A/en unknown
- 2022-05-16 TW TW111118217A patent/TW202313095A/zh unknown
- 2022-05-16 MX MX2023013554A patent/MX2023013554A/es unknown
- 2022-05-16 AU AU2022275786A patent/AU2022275786C1/en active Active
- 2022-05-16 US US18/021,802 patent/US20230302085A1/en active Pending
- 2022-05-16 LT LTEPPCT/US2022/029462T patent/LT4185318T/lt unknown
- 2022-05-16 EP EP25189523.1A patent/EP4647125A3/en active Pending
- 2022-05-16 ES ES22728724T patent/ES3041647T3/es active Active
- 2022-05-16 BR BR112023023002A patent/BR112023023002A2/pt unknown
- 2022-05-16 WO PCT/US2022/029462 patent/WO2022245739A1/en not_active Ceased
- 2022-05-16 EP EP22728724.0A patent/EP4185318B1/en active Active
- 2022-05-16 PE PE2023003023A patent/PE20240922A1/es unknown
- 2022-05-16 PL PL22728724.0T patent/PL4185318T3/pl unknown
- 2022-05-16 CA CA3190663A patent/CA3190663A1/en active Pending
- 2022-05-16 HR HRP20251282TT patent/HRP20251282T8/hr unknown
- 2022-05-16 KR KR1020237013896A patent/KR20240008821A/ko active Pending
- 2022-05-16 RS RS20251029A patent/RS67369B1/sr unknown
- 2022-05-16 JP JP2023513604A patent/JP2024519629A/ja active Pending
- 2022-05-16 DK DK22728724.0T patent/DK4185318T3/da active
- 2022-05-16 PT PT227287240T patent/PT4185318T/pt unknown
- 2022-05-16 SI SI202230175T patent/SI4185318T1/sl unknown
-
2023
- 2023-11-06 JO JOJO/P/2023/0283A patent/JOP20230283A1/ar unknown
- 2023-11-14 CL CL2023003396A patent/CL2023003396A1/es unknown
-
2024
- 2024-10-02 CL CL2024002972A patent/CL2024002972A1/es unknown
-
2025
- 2025-04-29 CL CL2025001269A patent/CL2025001269A1/es unknown
- 2025-09-04 AU AU2025226774A patent/AU2025226774A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185318A1 (en) | 2023-05-31 |
| AU2025226774A1 (en) | 2025-09-25 |
| AU2022275786A1 (en) | 2023-04-06 |
| EP4185318B1 (en) | 2025-09-03 |
| HRP20251282T8 (hr) | 2025-12-19 |
| BR112023023002A2 (pt) | 2024-01-23 |
| TW202313095A (zh) | 2023-04-01 |
| FI4185318T3 (fi) | 2025-10-13 |
| AU2022275786B2 (en) | 2025-06-05 |
| RS67369B1 (sr) | 2025-11-28 |
| JP2024519629A (ja) | 2024-05-21 |
| US20230302085A1 (en) | 2023-09-28 |
| CL2025001269A1 (es) | 2025-08-22 |
| PE20240922A1 (es) | 2024-04-30 |
| CA3190663A1 (en) | 2022-11-24 |
| HRP20251282T1 (hr) | 2025-12-05 |
| JOP20230283A1 (ar) | 2023-11-06 |
| MX2023013554A (es) | 2023-11-29 |
| PL4185318T3 (pl) | 2026-01-12 |
| PT4185318T (pt) | 2025-09-29 |
| DK4185318T3 (da) | 2025-09-29 |
| SI4185318T1 (sl) | 2025-10-30 |
| IL308505A (en) | 2024-01-01 |
| EP4647125A2 (en) | 2025-11-12 |
| LT4185318T (lt) | 2025-11-10 |
| CL2024002972A1 (es) | 2025-01-24 |
| WO2022245739A1 (en) | 2022-11-24 |
| EP4647125A3 (en) | 2026-01-28 |
| AU2022275786A8 (en) | 2023-04-20 |
| KR20240008821A (ko) | 2024-01-19 |
| AU2022275786C1 (en) | 2025-12-11 |
| ES3041647T3 (en) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025001269A1 (es) | Antagonistas del vegf en dosis alta para el tratamiento de trastornos oculares angiogénicos. | |
| MX2024011079A (es) | Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos | |
| MX2021014728A (es) | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CL2020001138A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x. | |
| MX2021005898A (es) | Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2021001439A (es) | Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio. | |
| MX2018010693A (es) | Compuestos biciclicos para diagnostico y terapia. | |
| MX2021006575A (es) | Composiciones y metodos para el tratamiento de trastornos del higado. | |
| MX385357B (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| CL2024002718A1 (es) | Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos. | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| CL2020001140A1 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x. | |
| CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
| MX394875B (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| CL2017001024A1 (es) | Formulación de buprenorfina inyectable | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| CL2025002297A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa. | |
| MX2018008272A (es) | Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos. |